Literature DB >> 26304840

The role of depression chronicity and recurrence on neurocognitive dysfunctions in HIV-infected adults.

Lucette A Cysique1,2,3,4,5, Nadene Dermody6,7, Andrew Carr8,9,6,10, Bruce J Brew8,9,6,10, Maree Teesson10.   

Abstract

Research assessing whether major depressive disorders (MDD) impacts neurocognitive functions in HIV+ persons has yielded inconsistent results. However, none have considered the role of MDD remission, chronicity, and stability on treatment. Ninety-five HIV+ adults clinically stable on combined antiretroviral treatment completed a psychiatric interview, a depression scale, a neuropsychological, daily living, and cognitive complaints assessments at baseline and 18 months. Participants were screened for current (within 12 months of study entry) alcohol and/or substance use disorder. History of alcohol and/or substance abuse disorder prior to the 12 months entry screen and MDD treatments were recorded. Participants were grouped into two psychiatric nomenclatures: (1) lifetime: no MD episode (MDE), single MDE life-event treated and fully remitted, chronic MDD treated and stable, chronic MDD treated and unstable, and baseline untreated MDE; (2) recent: last 2 years MDE (yes or no). We found that lifetime and recent psychiatric history were more strongly associated with decreased in independence in daily living and cognitive complaints than with baseline neuropsychological performance. However, lack of full remission, instability on treatment in chronic MDD, and severity of symptoms in current MDE were factors in whether MDD impacted baseline neuropsychological performance. Depressive symptoms improved at follow-up in those with baseline moderate-severe symptoms, and MDD was not associated with neurocognitive change at 18 months. A history of alcohol and/or substance abuse disorder was significantly more frequent in those with treated and unstable chronic MDD but it was not associated with neuropsychological performance. MDD recurrence, chronicity profiles, and associated comorbidities are keys factors to understand any potential impact on neurocognitive abilities in HIV infection. More comprehensive consideration of these complex effects could serve at constructively updating the HAND diagnostic criteria.

Entities:  

Keywords:  AIDS; Depression; HIV; Longitudinal study; Major depressive disorder; Neuropsychological functions

Mesh:

Year:  2015        PMID: 26304840     DOI: 10.1007/s13365-015-0368-5

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  28 in total

Review 1.  Remission versus response: the new gold standard of antidepressant care.

Authors:  Martin B Keller
Journal:  J Clin Psychiatry       Date:  2004       Impact factor: 4.384

2.  Meta-analysis of the relationship between HIV infection and risk for depressive disorders.

Authors:  J A Ciesla; J E Roberts
Journal:  Am J Psychiatry       Date:  2001-05       Impact factor: 18.112

3.  Facial emotional processing in HIV infection: relation to neurocognitive and neuropsychiatric status.

Authors:  Tammy A Lane; Danielle M Moore; Jennifer Batchelor; Bruce J Brew; Lucette A Cysique
Journal:  Neuropsychology       Date:  2012-09-17       Impact factor: 3.295

4.  Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up.

Authors:  T Gibbie; A Mijch; S Ellen; J Hoy; C Hutchison; E Wright; P Chua; F Judd
Journal:  HIV Med       Date:  2006-03       Impact factor: 3.180

5.  Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change.

Authors:  Lucette A Cysique; Donald Franklin; Ian Abramson; Ronald J Ellis; Scott Letendre; Ann Collier; David Clifford; Benjamin Gelman; Justin McArthur; Susan Morgello; David Simpson; J Allen McCutchan; Igor Grant; Robert K Heaton
Journal:  J Clin Exp Neuropsychol       Date:  2011-03-07       Impact factor: 2.475

6.  Treatment of depression in individuals living with HIV/AIDS.

Authors:  Michelle M Primeau; Victoria Avellaneda; Dominique Musselman; Gilbert St Jean; Lourdes Illa
Journal:  Psychosomatics       Date:  2013-02-04       Impact factor: 2.386

7.  Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline.

Authors:  Igor Grant; Donald R Franklin; Reena Deutsch; Steven P Woods; Florin Vaida; Ronald J Ellis; Scott L Letendre; Thomas D Marcotte; J H Atkinson; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Justin C McArthur; Susan Morgello; David M Simpson; John A McCutchan; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Davey M Smith; Robert K Heaton
Journal:  Neurology       Date:  2014-05-09       Impact factor: 9.910

Review 8.  HIV and depression: 2008 review and update.

Authors:  Judith G Rabkin
Journal:  Curr HIV/AIDS Rep       Date:  2008-11       Impact factor: 5.071

9.  Prediction of the time-course pattern of remission in depression by using clinical, neuropsychological, and genetic variables.

Authors:  Esteve Gudayol-Ferré; Joan Guàrdia-Olmos; Maribel Peró-Cebollero; Ixchel Herrera-Guzmán; Beatriz Camarena; Carlos Cortés-Penagos; Jorge E Herrera-Abarca; Patricia Martínez-Medina
Journal:  J Affect Disord       Date:  2013-06-17       Impact factor: 4.839

Review 10.  Cognitive-behavioural interventions for mood and anxiety disorders in HIV: a systematic review.

Authors:  G Spies; L Asmal; S Seedat
Journal:  J Affect Disord       Date:  2013-05-17       Impact factor: 4.839

View more
  9 in total

1.  Associations between Depressive Symptomatology and Neurocognitive Impairment in HIV/AIDS.

Authors:  Sarah Tymchuk; Daniela Gomez; Noshin Koenig; M John Gill; Esther Fujiwara; Christopher Power
Journal:  Can J Psychiatry       Date:  2017-12-11       Impact factor: 4.356

2.  Cognition, Coping, and Psychological Distress in HIV.

Authors:  Nikhil Banerjee; Zachary T Goodman; Roger McIntosh; Gail Ironson
Journal:  AIDS Behav       Date:  2021-09-19

3.  Cognitive performance in a South African cohort of people with HIV and comorbid major depressive disorder.

Authors:  Anna J Dreyer; Sam Nightingale; Lena S Andersen; Jasper S Lee; Hetta Gouse; Steven A Safren; Conall O'Cleirigh; Kevin G F Thomas; John Joska
Journal:  J Neurovirol       Date:  2022-09-01       Impact factor: 3.739

Review 4.  The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review.

Authors:  Thomas M Gates; Lucette A Cysique
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749

5.  Cognitive change trajectories in virally suppressed HIV-infected individuals indicate high prevalence of disease activity.

Authors:  Chloe Gott; Thomas Gates; Nadene Dermody; Bruce J Brew; Lucette A Cysique
Journal:  PLoS One       Date:  2017-03-06       Impact factor: 3.240

6.  Socioeconomic factors explain suboptimal adherence to antiretroviral therapy among HIV-infected Australian adults with viral suppression.

Authors:  Krista J Siefried; Limin Mao; Stephen Kerr; Lucette A Cysique; Thomas M Gates; John McAllister; Anthony Maynard; John de Wit; Andrew Carr
Journal:  PLoS One       Date:  2017-04-03       Impact factor: 3.240

7.  Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV-negative controls.

Authors:  D De Francesco; J Underwood; E Bagkeris; M Boffito; F A Post; Pwg Mallon; J H Vera; I Williams; J Anderson; M Johnson; C A Sabin; A Winston
Journal:  HIV Med       Date:  2019-02-08       Impact factor: 3.180

8.  Cumulative Burden of Depression and Neurocognitive Decline Among Persons With HIV: A Longitudinal Study.

Authors:  Emily W Paolillo; Elizabeth C Pasipanodya; Raeanne C Moore; Brian W Pence; Joseph Hampton Atkinson; David J Grelotti; Igor Grant; Robert K Heaton; David J Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2020-07-01       Impact factor: 3.731

Review 9.  HIV-Associated Neurocognitive Disorders: A Global Perspective.

Authors:  Rowan Saloner; Lucette A Cysique
Journal:  J Int Neuropsychol Soc       Date:  2017-10       Impact factor: 2.892

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.